PE20142041A1 - Anticuerpos anti-il-36r - Google Patents
Anticuerpos anti-il-36rInfo
- Publication number
- PE20142041A1 PE20142041A1 PE2014000705A PE2014000705A PE20142041A1 PE 20142041 A1 PE20142041 A1 PE 20142041A1 PE 2014000705 A PE2014000705 A PE 2014000705A PE 2014000705 A PE2014000705 A PE 2014000705A PE 20142041 A1 PE20142041 A1 PE 20142041A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr1
- cdr2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN ANTICUERPO ANTI-IL-36R, QUE COMPRENDE: a) UNA REGION VARIABLE DE CADENA LIVIANA QUE CONTIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 26(L-CDR1); LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 35, 102, 103, 104, 105, 106 O 140 (L-CDR2); LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 44(L-CDR3); Y b) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 53(H-CDR1); LA SECUENCIA DE AMINOACIDOS SEC ID NO:62, 108, 109, 110 O 111 (H-CDR2); LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 72 (H-CDR3). SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD AUTOINMUNE.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161560554P | 2011-11-16 | 2011-11-16 | |
| US201261644111P | 2012-05-08 | 2012-05-08 | |
| US201261713713P | 2012-10-15 | 2012-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142041A1 true PE20142041A1 (es) | 2014-12-18 |
Family
ID=47215803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000705A PE20142041A1 (es) | 2011-11-16 | 2012-11-14 | Anticuerpos anti-il-36r |
Country Status (41)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2858350A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| RS67639B1 (sr) | 2011-11-16 | 2026-02-27 | Boehringer Ingelheim Int | Anti il-36r antitela |
| RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| WO2015138920A1 (en) * | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| RU2582569C2 (ru) * | 2014-07-24 | 2016-04-27 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом |
| EP3277321B1 (en) | 2015-04-01 | 2024-08-14 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| RU2745898C2 (ru) | 2015-04-15 | 2021-04-02 | Анаптисбайо, Инк. | Антитела, направленные против рецептора интерлейкина 36 (il-36r) |
| EP3307772B1 (en) * | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
| JP6654773B2 (ja) * | 2015-12-25 | 2020-02-26 | 国立大学法人名古屋大学 | インターロイキン３６受容体アンタゴニスト欠損症の治療薬 |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| JP7118073B2 (ja) | 2017-01-09 | 2022-08-15 | テサロ， インコーポレイテッド | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
| US20180273627A1 (en) * | 2017-03-27 | 2018-09-27 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| US11207294B2 (en) * | 2018-01-08 | 2021-12-28 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2 |
| WO2019177883A2 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| AU2019236105B2 (en) * | 2018-03-14 | 2025-07-31 | Boehringer Ingelheim International Gmbh | Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis |
| IL315703A (en) | 2018-07-16 | 2024-11-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| IL280013B2 (en) | 2018-07-16 | 2026-05-01 | Regeneron Pharmaceuticals Inc | Anti-IL36R antibodies |
| JP2022532812A (ja) | 2018-08-16 | 2022-07-20 | カンタージア アクチエボラーグ | 抗ｉｌ１ｒａｐ抗体組成物 |
| EP3856773A1 (en) * | 2018-09-28 | 2021-08-04 | Kyowa Kirin Co., Ltd. | Il-36 antibodies and uses thereof |
| US11884719B2 (en) * | 2018-12-21 | 2024-01-30 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
| TW202037604A (zh) * | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| EA202192405A1 (ru) | 2019-03-08 | 2022-01-13 | Бёрингер Ингельхайм Интернациональ Гмбх | Составы антител против il-36r |
| JP7811772B2 (ja) * | 2019-12-05 | 2026-02-06 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| AR120913A1 (es) * | 2019-12-27 | 2022-03-30 | Teijin Pharma Ltd | Anticuerpo que inhibe específicamente la señalización de il-36r |
| US20220010022A1 (en) | 2020-05-19 | 2022-01-13 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for the treatment of atopic dermatitis |
| EP4182022A1 (en) | 2020-07-17 | 2023-05-24 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses |
| WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| JP2023536851A (ja) * | 2020-07-30 | 2023-08-30 | アナプティスバイオ インコーポレイティッド | 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法 |
| KR20230079268A (ko) | 2020-09-30 | 2023-06-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 만성 염증성 통증의 치료를 위한 항-il-36r 항체 |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| EP4289863A4 (en) * | 2020-12-17 | 2025-04-09 | Shanghai Huaota Biopharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| WO2022166977A1 (zh) * | 2021-02-08 | 2022-08-11 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| MX2023010289A (es) | 2021-03-04 | 2023-09-11 | Boehringer Ingelheim Int | Uso de anticuerpos anti-il-36r en el tratamiento de la psoriasis pustulosa generalizada. |
| EP4305207A2 (en) | 2021-03-12 | 2024-01-17 | Boehringer Ingelheim International GmbH | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| KR20240004718A (ko) * | 2021-05-03 | 2024-01-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 스페솔리맙의 제조방법 |
| KR20240022546A (ko) * | 2021-06-18 | 2024-02-20 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항il-36r 항체 및 그의 사용 |
| EP4370550A1 (en) | 2021-07-12 | 2024-05-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| US20230049147A1 (en) | 2021-08-13 | 2023-02-16 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for the treatment of a fibrotic condition |
| WO2023052222A2 (en) | 2021-09-28 | 2023-04-06 | Boehringer Ingelheim International Gmbh | System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation |
| IL312360A (en) * | 2021-10-28 | 2024-06-01 | Abbvie Inc | Anti-amyloid beta antibodies and methods of using them |
| TW202323293A (zh) * | 2021-10-29 | 2023-06-16 | 新加坡商創響私人有限公司 | 新型抗ｉｌ－３６ｒ抗體 |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
| CN116574189A (zh) | 2023-01-30 | 2023-08-11 | 北京智仁美博生物科技有限公司 | 针对人il-36r和/或人il-1r3的多种抗体及其用途 |
| TW202434647A (zh) | 2023-02-21 | 2024-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Il-36r結合蛋白及其醫藥用途 |
| CN120835899A (zh) | 2023-03-09 | 2025-10-24 | 勃林格殷格翰国际有限公司 | 抗il-36r抗体用于治疗化脓性汗腺炎（hs）的用途 |
| KR20260025132A (ko) | 2023-06-09 | 2026-02-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 전신 농포성 건선(gpp)의 치료 및 예방 방법 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| AU687755B2 (en) | 1992-08-21 | 1998-03-05 | Genentech Inc. | Method for treating an LFA-1-mediated disorder |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| PT1003861E (pt) | 1997-08-01 | 2007-01-31 | Schering Corp | Proteínas de membrana de células de mamíferos;reagentes relacionados |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| AU2001247616B2 (en) * | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| EP1627927A3 (en) * | 2001-03-01 | 2006-06-07 | Epigenomics AG | Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
| CA2499891A1 (en) * | 2002-10-03 | 2004-04-15 | Large Scale Biology Corporation | Multimeric protein engineering |
| JP5364870B2 (ja) * | 2005-08-19 | 2013-12-11 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2662549C (en) * | 2006-09-08 | 2014-10-28 | Amgen Inc. | Il-1 family variants |
| WO2008133857A1 (en) | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| BRPI0813966A8 (pt) | 2007-06-29 | 2016-02-10 | Schering Corp | Usos de mdl-1 |
| KR20110048536A (ko) | 2008-08-28 | 2011-05-11 | 와이어쓰 엘엘씨 | 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도 |
| RS67639B1 (sr) | 2011-11-16 | 2026-02-27 | Boehringer Ingelheim Int | Anti il-36r antitela |
| RU2745898C2 (ru) | 2015-04-15 | 2021-04-02 | Анаптисбайо, Инк. | Антитела, направленные против рецептора интерлейкина 36 (il-36r) |
-
2012
- 2012-11-14 RS RS20260044A patent/RS67639B1/sr unknown
- 2012-11-14 HR HRP20251675TT patent/HRP20251675T1/hr unknown
- 2012-11-14 DK DK19169065.0T patent/DK3536710T3/da active
- 2012-11-14 SI SI201232101T patent/SI3536710T1/sl unknown
- 2012-11-14 HU HUE12788410A patent/HUE047437T2/hu unknown
- 2012-11-14 CN CN202410673612.0A patent/CN118496365A/zh active Pending
- 2012-11-14 KR KR1020207026736A patent/KR20200110476A/ko not_active Ceased
- 2012-11-14 FI FIEP19169065.0T patent/FI3536710T3/fi active
- 2012-11-14 PT PT127884104T patent/PT2780373T/pt unknown
- 2012-11-14 LT LTEP19169065.0T patent/LT3536710T/lt unknown
- 2012-11-14 US US13/676,511 patent/US9023995B2/en active Active
- 2012-11-14 CN CN202410673234.6A patent/CN118515766A/zh active Pending
- 2012-11-14 HR HRP20191835TT patent/HRP20191835T1/hr unknown
- 2012-11-14 EP EP12788410.4A patent/EP2780373B1/en active Active
- 2012-11-14 CN CN201280054425.XA patent/CN104080808B/zh active Active
- 2012-11-14 ES ES12788410T patent/ES2755732T3/es active Active
- 2012-11-14 MX MX2014005759A patent/MX347164B/es active IP Right Grant
- 2012-11-14 CA CA2852994A patent/CA2852994C/en active Active
- 2012-11-14 CN CN201610916419.0A patent/CN107007833B/zh active Active
- 2012-11-14 LT LTEP12788410.4T patent/LT2780373T/lt unknown
- 2012-11-14 AU AU2012339734A patent/AU2012339734B2/en active Active
- 2012-11-14 CN CN202011390234.3A patent/CN112812183B/zh active Active
- 2012-11-14 PT PT191690650T patent/PT3536710T/pt unknown
- 2012-11-14 GE GEAP201713499A patent/GEP20186816B/en unknown
- 2012-11-14 SI SI201231692T patent/SI2780373T1/sl unknown
- 2012-11-14 RS RSP20191179 patent/RS59248B1/sr unknown
- 2012-11-14 PE PE2014000705A patent/PE20142041A1/es active IP Right Grant
- 2012-11-14 PL PL12788410T patent/PL2780373T3/pl unknown
- 2012-11-14 EA EA201400579A patent/EA031948B1/ru not_active IP Right Cessation
- 2012-11-14 UA UAA201406586A patent/UA115540C2/uk unknown
- 2012-11-14 KR KR1020147013267A patent/KR102038310B1/ko active Active
- 2012-11-14 BR BR112014011594-0A patent/BR112014011594B1/pt active IP Right Grant
- 2012-11-14 PL PL19169065.0T patent/PL3536710T3/pl unknown
- 2012-11-14 SG SG11201402283PA patent/SG11201402283PA/en unknown
- 2012-11-14 EP EP19169065.0A patent/EP3536710B1/en active Active
- 2012-11-14 ES ES19169065T patent/ES3058874T3/es active Active
- 2012-11-14 DK DK12788410T patent/DK2780373T3/da active
- 2012-11-14 WO PCT/US2012/064933 patent/WO2013074569A1/en not_active Ceased
- 2012-11-14 KR KR1020197030980A patent/KR102159109B1/ko active Active
- 2012-11-14 AP AP2014007571A patent/AP2014007571A0/xx unknown
- 2012-11-14 MY MYPI2019000058A patent/MY195289A/en unknown
- 2012-11-14 JP JP2014542388A patent/JP6289375B2/ja active Active
- 2012-11-15 TW TW101142698A patent/TWI573804B/zh active
- 2012-11-15 AR ARP120104313A patent/AR089178A1/es active IP Right Grant
- 2012-11-16 UY UY0001034456A patent/UY34456A/es active IP Right Grant
-
2014
- 2014-04-04 ZA ZA2014/02491A patent/ZA201402491B/en unknown
- 2014-04-13 IL IL232100A patent/IL232100B/en active IP Right Grant
- 2014-04-29 CL CL2014001123A patent/CL2014001123A1/es unknown
- 2014-05-14 CO CO14103887A patent/CO7020871A2/es unknown
- 2014-05-16 PH PH12014501108A patent/PH12014501108B1/en unknown
- 2014-06-13 EC ECIEPI20144976A patent/ECSP14004976A/es unknown
-
2015
- 2015-04-01 US US14/676,365 patent/US10550189B2/en active Active
-
2018
- 2018-02-06 JP JP2018019080A patent/JP6719490B2/ja active Active
-
2019
- 2019-11-12 CY CY20191101185T patent/CY1122278T1/el unknown
- 2019-12-17 US US16/717,413 patent/US20200231684A1/en not_active Abandoned
-
2020
- 2020-01-14 IL IL272035A patent/IL272035A/en unknown
- 2020-06-16 JP JP2020103873A patent/JP2020156506A/ja active Pending
-
2023
- 2023-05-23 CY CY2023014C patent/CY2023014I1/el unknown
- 2023-05-26 LT LTPA2023518C patent/LTC2780373I2/lt unknown
- 2023-05-30 NO NO2023024C patent/NO2023024I1/no unknown
- 2023-05-31 LU LU00308C patent/LUC00308I2/fr unknown
- 2023-05-31 FR FR23C1023C patent/FR23C1023I2/fr active Active
- 2023-05-31 NL NL301233C patent/NL301233I2/nl unknown
- 2023-06-01 FI FIC20230020C patent/FIC20230020I1/fi unknown
- 2023-06-05 HU HUS2300021C patent/HUS2300021I1/hu unknown
-
2024
- 2024-08-27 US US18/815,907 patent/US20240409648A1/en active Pending
-
2025
- 2025-01-03 NO NO2025001C patent/NO2025001I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| AR082916A1 (es) | Moleculas de union a 4-1bb | |
| BR112013032899A2 (pt) | anticorpos anti-axl e utilizações dos mesmos | |
| PE20080036A1 (es) | Anticuerpos humanos para la interleucina-13 (il13) | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| NZ599438A (en) | Humanized antibodies against human il-22ra | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| NZ629829A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20141188A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| PE20181014A1 (es) | Agentes, usos y metodos para el tratamiento | |
| BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
| PE20200173A1 (es) | Anticuerpos anti-trkb | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| EA201391453A1 (ru) | Новое антитело против рецептора il-23 человека | |
| CO2018001010A2 (es) | Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh | |
| MX349235B (es) | Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs). | |
| RU2015150723A (ru) | Моноклональное антитело против cxcr5 | |
| PE20220287A1 (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |